drugset / Trial / NCT05136664
Trial Evaluating the Efficacy and Safety of Patiromer in Chinese Subjects
Phase 3
Completed
262 enrolled
Vifor Fresenius Medical Care Renal Pharma
Tigermed Consulting Co., Ltd · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This is a multicentre, 2-part, single-blind, randomised, withdrawal, placebo-controlled study, that includes a 4-week patiromer treatment phase (Part A) followed by an 8-week randomised placebo-controlled withdrawal phase (Part B) and a 2-week follow-up period.
Timeline
- Start
- 2022-02-10
- Primary completion
- 2025-11-18
- Completion
- 2025-11-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Patiromer | Other / unclassified | 8.4 g | — |